Rhee, E J <br/><br/>
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.  [electronic resource] 

 -  Diabetes, obesity & metabolism  Jun 2013 
 - 523-30 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12060  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Asian People<br/>Blood Glucose--drug effects<br/>Diabetes Mellitus, Type 2--blood<br/>Dipeptidyl-Peptidase IV Inhibitors--therapeutic use<br/>Double-Blind Method<br/>Fasting<br/>Female<br/>Glucagon-Like Peptide 1--drug effects<br/>Glucose Tolerance Test<br/>Glycated Hemoglobin--drug effects<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Male<br/>Metformin--therapeutic use<br/>Middle Aged<br/>Piperidones--therapeutic use<br/>Pyrazines--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Republic of Korea--epidemiology<br/>Risk Reduction Behavior<br/>Sitagliptin Phosphate<br/>Treatment Outcome<br/>Triazoles--therapeutic use